Manchester named as one of six centres of excellence in UK Precision Medicine network
As partners within the Northern Health Science Alliance,
Central Manchester Hospitals NHS Foundation Trust and The
University of Manchester are set to become part of regional
precision medicine activities within the UK-wide network. This also
supports the work of MAHSC, of which both organisations are
members, into discovery science and translational
The other initial locations announced by the Precision Medicine
Catapult, the UK's innovation centre for precision medicine, are
Belfast, Cardiff, Glasgow, Leeds and Oxford.
Precision medicine is an approach where individual patients
receive the care that is most appropriate for them, taking into
account individual variability in genes, environment, and lifestyle
for each person.
The Precision Medicine Catapult will leverage off local
infrastructure in these precision medicine hotspots, and will also
enable centres of excellence to apply for collaborative research
grants and other funds in partnership with other organisations, and
will be working with industry and academia on joint projects.
Each centre will act as a hub for regional precision medicine
activities within the UK-wide network, co-ordinated from the
Cambridge headquarters. The Catapults are a UK Government
initiative, established and part-funded through Innovate UK.
The centres of excellence will work on locally driven programmes
and use the Precision Medicine Catapult network to harness the
breadth of UK expertise, developing innovative technologies and
solutions for broader use across the UK's healthcare sector.
John McKinley, CEO of the Precision Medicine Catapult, said,
'We're delighted to announce the location of these centres of
excellence, each with access to a unique blend of regional
expertise. Project development work has been ongoing across the UK
and we will be launching offices and related programmes over the
coming months. As well as growing the UK's strong position in
precision medicine, we believe our network will deliver health and
economic impact at a local and national level.'
Universities and Science Minister Jo Johnson said, 'The UK is a
world leader in the life sciences and that's in no small part
thanks to innovative firms and academics across the country. As a
One Nation Government we are committed to strengthening our
capabilities in this crucial sector. These centres of excellence
will join together a network of researchers to develop precision
medicine technologies that will save lives and support growth in
our world-class life science industry.'
Ruth McKernan, Innovate UK Chief Executive, said, 'It is
important that we draw on the UK's research and clinical expertise
in precision medicine from across the country. Understanding which
types of patients will benefit most from treatments requires
effective use of diagnostic testing and data-based insights. The
Precision Medicine Catapult's reach to patients for clinical trials
purposes will be enhanced through the national network of centres
A physical presence will be established at each centre, with
local recruitment to build expert teams. The centres will work
collaboratively with local, national and global stakeholders
including government, academia, health systems and SMEs, with broad
industry engagement to identify and resolve barriers to building a
leading UK precision medicine industry.
Expertise in core areas such as data analytics, clinical trials,
regulatory affairs and health economics will be based at the
Cambridge head office, along with business services. Activities
across all centres will include support of major clinical and data
programmes, such as testing of new precision medicine ready
clinical trial models and the development of NHS adoption
Development of new diagnostics, IT and e-health systems are also
fundamental to the success of the UK's precision medicine industry,
and the Precision Medicine Catapult will work with government
initiatives, industry and regulators to build the sector.
Precision medicine uses diagnostic tests and data-based insights
to understand a patient's disease more precisely and so select
treatments with more predictable, safer, cost-effective outcomes.
The UK's research and clinical expertise, combined with
government's major investment in relevant research infrastructure,
has placed it in a leading position in this area.